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Summary
The epithelial chloride channel CFTR is a glycoprotein that is modified by two N-linked
oligosaccharides. The most common mutant CFTR protein in patients with cystic fibrosis, ΔF508,
is misfolded and retained by ER quality control. As oligosaccharide moieties of glycoproteins are
known to mediate interactions with ER lectin chaperones, we investigated the role of N-linked
glycosylation in the processing of wild-type and ΔF508 CFTR. We found that N-glycosylation and
ER lectin interactions are not major determinants of trafficking of wild-type and ΔF508 from the ER
to the plasma membrane. Unglycosylated CFTR, generated by removal of glycosylation sites or
treatment of cells with the N-glycosylation inhibitor tunicamycin, did not bind calnexin, but did
traffic to the cell surface and exhibited chloride channel activity. Most importantly, unglycosylated
Δ F508 CFTR still could not escape quality control in the early secretory pathway and remained
associated with the ER. However, the absence of N-linked oligosaccharides did reduce the stability
of wild-type CFTR, causing significantly more-rapid turnover in post-ER compartments.
Surprisingly, the individual N-linked carbohydrates do not play equivalent roles and modulate the
fate of the wild-type protein in different ways in its early biosynthetic pathway.
Keywords
CFTR; Glycosylation; Glycoprotein; Processing; Calnexin; EDEM
Introduction
The carbohydrate moieties of glycoproteins often do not play a role in their catalytic activities
but contribute to stability, trafficking and localization within cells (Chow and Forte, 1995; de
Souza and Simon, 2002; Hendriks et al., 2004; Li et al., 2007; Standley and Baudry, 2000).
Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), including
ΔF508, which is present in most cystic fibrosis patients, result in thermolability and
mislocalization of the ion channel protein within epithelial cells (Cheng et al., 1990; Denning
et al., 1992). As a result, the mutated nascent polypeptide cannot pass ER quality control.
*Author for correspondence (e-mail: gentzsch@med.unc.edu)
NIH Public Access
Author Manuscript
J Cell Sci. Author manuscript; available in PMC 2009 May 5.
Published in final edited form as:













Although ΔF508 acquires core N-linked oligosaccharide chains in the ER, these are not
extended because it cannot progress from the ER to the Golgi, where the glycosyltransferases
required for chain extension are localized. Even the wild-type protein achieves a mature
conformation state very inefficiently, so that only about a third of the core-glycosylated wild-
type polypeptides are exported from the ER to the Golgi and, once glycosylation is complete
there, progress to the plasma membrane (Lukacs et al., 1994; Ward and Kopito, 1994). Thus,
the presence or absence of the complex oligosaccharide chains is diagnostic of the extent to
which conformational maturation has enabled ER export to occur.
However, there have been proposals that CFTR oligosaccharide chains and their interactions
with lectin chaperones in the ER are actively involved in the extent to which wild-type or
mutant CFTR transits through steps in the early secretory pathway. It has been reported that
ΔF508 CFTR stability and processing are modulated by the ER lectin calnexin (Okiyoneda et
al., 2004; Okiyoneda et al., 2002), and inhibition of the association of CFTR with calnexin has
been claimed to promote ΔF508 maturation (Egan et al., 2002; Egan et al., 2004; Harada et al.,
2007; Norez et al., 2006a; Norez et al., 2006b); however, this effect could not be confirmed
by others (Dragomir et al., 2004; Farinha and Amaral, 2005; Grubb et al., 2006; Loo et al.,
2004; Song et al., 2004).
Here, we have addressed this issue in both non-polarized and polarized cells by assessing the
effects of genetic and pharmacological prevention of the addition of one or both of the N-linked
oligosaccharide chains on the trafficking and localization of wild-type and ΔF508 CFTR.
Whereas these chains do not appear to be the primary determinants of ER retention or export,
they do influence the stability and lifetime of wild-type CFTR, and the individual chains have
different impacts on the fate of the protein in the ER.
Results
N-linked oligosaccharides of CFTR are required for calnexin binding, but not for channel
function
The ER lectin chaperone calnexin has been shown to bind to monoglucosylated N-linked
oligosaccharides of many glycoproteins until conformational maturation is complete (Helenius
and Aebi, 2001; Parodi, 2000; Pind et al., 1994). CFTR binds to calnexin (Pind et al., 1994)
and we mutated the two potential N-linked glycosylation sites of human CFTR (Fig. 1) to test
whether this interaction is disrupted by removal of N-linked oligosaccharides. Mutation of
native N-linked glycosylation sites (N894D/N900D) and treatment of cells with tunicamycin
resulted in expression of unglycosylated CFTR (Fig. 2A). Calnexin co-immunoprecipitated
with wild-type CFTR, whereas its soluble homolog calreticulin did not (supplementary
material Fig. S2). The unglycosylated CFTR variant did not interact with calnexin (Fig. 2B)
and, thus, the binding was solely mediated by the oligosaccharides. The unglycosylated CFTR,
created either by mutation of the two glycosylation sites or by inhibition of N-linked
glycosylation with tunicamycin, is functional and has similar channel properties to wild-type
CFTR (Fig. 2C). Thus, N-linked oligosaccharides of wild-type CFTR are required for calnexin
binding, but their absence does not prevent the protein from reaching a functional state.
Inhibition of interactions with ER lectin chaperones does not affect localization of wild-type
or ΔF508 CFTR
To analyze whether the N-linked oligosaccharides are involved in retention of ΔF508 CFTR
at the ER, we expressed ΔF508 with mutations at both N-glycosylation sites (ΔF508 N894D/
N900D) (Fig. 3A). Similar to non-glycosylated wild-type CFTR, ΔF508 N894D/N900D did
not interact with calnexin (Fig. 3B). To test the influence of the absence of N-linked
oligosaccharides on the processing of ΔF508 CFTR, we analyzed localization and cAMP-
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stimulated channel activity at the cell surface. At physiological temperature (37°C), ΔF508
localized only to the ER regardless of whether or not it was glycosylated (ΔF508 or ΔF508
N894D/N900D), as observed by immunolocalization of permeabilized cells (Fig. 3C). Staining
of the surface CFTR of intact cells with an antibody recognizing an external epitope confirmed
that unglycosylated ΔF508 N894D/N900D was not present at the plasma membrane (Fig. 3D).
ΔF508 CFTR is a temperature-sensitive mutation with the consequence that the protein cannot
mature conformationally at 37°C, but is able to avoid ER quality control and proceed to the
plasma membrane at 27°C (Denning et al., 1992). When cells were incubated at 27°C, both
glycosylated ΔF508 and unglycosylated ΔF508 N894D/N900D could be detected at the cell
surface (Fig. 3D). Thus, the absence of N-linked oligosaccharides did not seem to affect
intracellular localization and processing of ΔF508 CFTR.
Consistent with these findings, a functional assessment of the influence of the lack of
glycosylation indicated that the wild-type protein was not severely impaired, nor the mutant
facilitated, in reaching the cell surface (Fig. 3E). Cells expressing unglycosylated CFTR
N894D/N900D showed a robust chloride efflux response to cAMP-elevating stimuli, whereas
ΔF508 N894D/N900D did not display any activity, reflecting the absence of the channel protein
at the plasma membrane.
To determine the influence of glycosylation on ER-to-cell-surface trafficking in a more native
CFTR environment (Kreda et al., 2005), we transduced well-polarized human primary airway
epithelial cells with viral vectors to express glycosylated and unglycosylated forms of wild-
type and ΔF508 CFTR. At 37°C, the wild-type protein was observed primarily in its native
location in the apical membrane regardless of its glycosylation state, whereas neither
glycosylated ΔF508 nor unglycosylated ΔF508 N894D/N900D CFTR was able to reach the
apical membrane and was instead localized intracellulary (Fig. 3F). However, when the cells
were cultured at 27°C, the mutant protein became distinctly localized to the apical
compartment, independently of its glycosylation state (Fig. 3G). Thus, the glycosylation state
and the consequent interaction with calnexin did not appear to be primary determinants of the
trafficking of either wild-type or ΔF508 CFTR, in either polarized or non-polarized cells.
In addition to calnexin, another ER lectin, EDEM (ER degradation-enhancing α-mannosidase-
like protein; EDEM1), is able to bind CFTR (Fig. 4A) (Gnann et al., 2004). Overexpression
of EDEM enhances the rate of ER-associated degradation (ERAD) of CFTR (Fig. 4B) (Farinha
and Amaral, 2005;Gnann et al., 2004). We used glycosidase inhibitors to perturb the interaction
of EDEM with nascent ΔF508 CFTR. Both 1-deoxymannojirimycin (DMM) and kifunensine
inhibit the cleavage of a mannose residue required for interaction with EDEM (Elbein et al.,
1990;Fuhrmann et al., 1984;Oda et al., 2003). Neither of these drugs influenced the residence
of ΔF508 CFTR in the ER (Fig. 4C) or increased the amount of the mutant protein at the cell
surface (Fig. 4D). A similar pharmacological experiment with castanospermine, which inhibits
the glucosidase I activity (Sasak et al., 1985) necessary for calnexin binding, yielded the same
result, consistent with our previous observations. Thus, neither of these ER lectins appears to
be responsible for retention of the misassembled ΔF508 CFTR protein in the ER.
Oligosaccharides impact CFTR maturation and turnover
Although the presence or absence of both oligosaccharide chains does not have a major effect
on the steady-state localization of CFTR, the influence of the two together or individually on
turnover is unknown. We performed pulse-chase labeling experiments with the variant in which
both N-glycosylation sites were mutated, as in the localization experiments (Fig. 3), and also
with variants with each individual site substituted. Prior to these kinetic experiments, the
possibility that the two chains might have different effects on processing and turnover had not
been explored. Western blots comparing the wild-type protein and the three different variants
(Fig. 5A) detected only the unglycosylated form of the double mutant. The single-chain N894D
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species primarily formed a single band of mobility intermediate between the unglycosylated
and wild-type forms, presumably with a complex N-linked chain at the N900 site. However,
the other single-site variant, N900D, generated two strong bands, one with a similar mobility
to that of N894D, probably representing the presence of the other single chain, and another
more rapidly migrating band, most likely representative of a core rather than complex
oligosaccharide chain at this site. The identity of the core-glycosylated forms of N894D and
N900D was confirmed by digestion with endoglycosidase H, which selectively deglycosylates
unprocessed core-glycosylated proteins and thus converted CFTR to a band with the same
mobility as the N894D/N900D double mutant (Fig. 5B). Thus, the individual N-glycosylation
sites are utilized when only one of them is present, and they undergo core and complex
glycosylation. However, it appears that the nascent chain with only the N894 site available
(N900D), progresses from the core to complex glycosylated state inefficiently.
As a means of further probing the difference between the two single-oligosaccharide-chain
species, we tested the susceptibility of each to enzymatic removal of the oligosaccharides with
peptide:N-glycanase (PNGase). As shown in Fig. 5C, there was a striking difference in the
ease of removal of the two chains. The oligosaccharide at the N900 site was efficiently attached
(N894D in Fig. 5A) and was relatively refractory to removal by the PNGase (Fig. 5C, panel
N894D), whereas that at the other site was rapidly removed to yield the unglycosylated species
(Fig. 5C, compare panel N900D with N894D/N900D). Interestingly, the wild-type protein (Fig.
5C, panel CFTR) behaved similarly to N894D, strongly suggesting that its two chains were
differentially sensitive in the same way as when present individually. The basis for this major
difference is not yet clear, but emphasizes the non-identity of chains attached at the two sites.
To examine possible kinetic differences in the maturation and turnover of CFTR with either
oligosaccharide chain, pulse-chase experiments were performed. Fig. 6A compares the
conversion of the pulse-labeled core-glycosylated forms of each with the wild-type and
unglycosylated forms and their turnover during long-term chases. Although unglycosylated
N894D/N900D can mature conformationally and reach the cell surface where it functions (Figs
2 and 3), it clearly turns over much more rapidly than the wild-type protein (Fig. 6A). By
contrast, the single-chain species N894D appeared to mature as effectively as the wild-type
protein, with its two chains. As had been suggested by the western blots (Fig. 5A), the N900D
species matured much less effectively than the wild-type or N894D proteins, and the mature
product appeared to turn over faster than wild-type CFTR. To test the possibility that the
differential impact of the two chains might be exerted at the early ER stage of processing,
similar pulse-chase experiments were carried out in cells treated with brefeldin A (BFA) to
prevent transport beyond the ER compartment. Several important results emerged from these
experiments. First, turnover of the unglycosylated protein was similar to that of the wild-type
protein (Fig. 6B,C), even though there was a large difference when the proteins were allowed
to progress beyond the ER (Fig. 6A). Therefore, the complete absence of the oligosaccharide
chains apparently has little influence on the turnover of the immature nascent chain in the ER,
but strongly shortens its lifetime in more-distal compartments. The N894D species also turned
over at a very similar rate to the wild-type protein in the BFA-exposed cells (Fig. 6B,C). Hence,
this glycan at N900, which is relatively resistant to removal by N-glycanase, seems to be the
dominant determinant of the ‘normal’ behavior of the wild-type protein in both the early and
late stages of the secretory pathway. Again, in the BFA-treated cells, the N900D species was
distinctly different from the others, turning over much more rapidly (Fig. 6B,C). Thus, N900D
CFTR modified with an N-linked oligosaccharide chain only at the N894 site is clearly
recognized differently in the ER, and enters primarily into a degradative pathway with a
reduced proportion achieving maturation. This was further confirmed by the application of the
proteasomal inhibitor ALLN, which significantly stabilized CFTR N900D, but neither CFTR
N894D nor the double mutant (supplementary material Fig. S4).
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To investigate whether the single-glycosylation-site mutants have differential preference for
ER lectins, we analyzed their interaction with calnexin and EDEM. We found that N894D
interacted more strongly with calnexin than did N900D (Fig. 7A), but more of the latter was
found in association with EDEM (Fig. 7B). The oligosaccharide at position 900 might mediate
prolonged or preferential association with calnexin, as reflected in the decreased binding of
the N894D mutant to EDEM but unaffected interaction with calnexin as compared with wild-
type CFTR. By contrast, the oligosaccharide at position 894, which seems to direct the single
mutant primarily into a degradative pathway at the ER, might support EDEM interaction in
the N900D mutant, which is similar to that of the wild-type protein, whereas binding to calnexin
is reduced.
Interestingly, a small amount of non-glycosylated CFTR was found to co-immunoprecipitate
with EDEM. This could indicate that the CFTR protein itself, not just the oligosaccharides, is
involved in this interaction. The ability of EDEM to interact with non-glycosylated substrate
has been described previously. EDEM was found to bind to the α1-antitrypsin variant null
Hong Kong (NHK), even when all the asparagines of the three potential N-glycosylation sites
had been mutated (Oda et al., 2006), and the ER lectin also associated with ricin that did not
contain any carbohydrates (Slominska-Wojewodzka et al., 2006). Another possible
explanation for the association of non-glycosylated CFTR and EDEM is through an indirect
interaction, mediated by another protein that is part of a chaperone complex. Possible
candidates are, for example, members of the derlin family that have been shown to be involved
in ER quality control and are known to interact with CFTR and EDEM (Oda et al., 2006;
Younger et al., 2006).
Discussion
The mutant human CFTR protein ΔF508, which is present in 90% of cystic fibrosis patients,
has some residual chloride channel activity (Dalemans et al., 1991; Drumm et al., 1991).
However, it does not mature and traffic to the cell surface but is retained at the ER and
eliminated by the proteasome (Jensen et al., 1995; Ward et al., 1995). Therefore, the
mechanisms resulting in the different fates of the wild-type and mutant proteins are subject to
intense investigation.
Although an increasing number of proteins, including components of the Hsp70 and Hsp90
chaperone complexes, have been identified that interact with ΔF508 CFTR at the ER and affect
its processing to some extent, the detailed mechanism of its ER retention is not completely
understood (Amaral and Kunzelmann, 2007; Riordan, 2008; Wang et al., 2006). It has been
repeatedly proposed that calnexin might be a target for developing a therapeutic approach to
rescue processing of ΔF508 CFTR and therefore it is important to clarify whether or not ΔF508
CFTR is retained by this lectin.
Numerous membrane glycoproteins have been shown to interact with calnexin, but in many
cases it has not been clearly demonstrated that calnexin is a primary determinant of ER retention
or export (Dickson et al., 2002; Halaban et al., 2000; Lu et al., 2003; Morello et al., 2001;
Nagaya et al., 1999; Rigot et al., 1999). We show in this study that the failure to export the
ΔF508 CFTR from the ER is independent of N-glycosylation and ER lectin interactions. The
mutant protein was not able to reach the cell surface when interactions with ER-lectin
chaperones were inhibited either by removal of N-linked glycosylation sites or by
pharmacological inhibition (Figs 3 and 4). Another very recent study confirmed, using calnexin
knockout mice, that calnexin is not necessary for ER retention of ΔF508 CFTR (Okiyoneda et
al., 2008). This is in contrast to some other membrane glycoproteins, such as the major
histocompatibility complex class I molecules and influenza hemagglutinin, which are retained
Chang et al. Page 5













by calnexin when not correctly assembled (Brothers et al., 2006; Jackson et al., 1994; Molinari
et al., 2004; Rajagopalan and Brenner, 1994; Zhang et al., 1997).
A lack of N-linked oligosaccharides also did not affect sorting of wild-type CFTR to the plasma
or apical membrane. Unlike CFTR, the N-glycans of some other membrane proteins, such as
the β-subunits of the Na,K-ATPase or the gastric H,K-ATPase, carry apical sorting information
(Vagin et al., 2007). Other examples of membrane proteins for which N-linked glycosylation
is required for efficient trafficking to the cell surface are shaker K+ channels (de Souza and
Simon, 2002), the glutamate receptor (Standley and Baudry, 2000), NKCC2 (SLC12A1)
(Paredes et al., 2006) and aquaporin 2 (Hendriks et al., 2004).
We found that complete removal of N-linked glycosylation at both sites of CFTR did however
influence turnover of the mature CFTR protein in post-ER compartments. The non-
glycosylated double mutant turned over rapidly but behaved like wild-type CFTR in the
presence of brefeldin A, which blocks transport from the ER to the Golgi apparatus (Fig. 6B,C).
Farinha and Amaral (Farinha and Amaral, 2005) observed a shortened half-life of CFTR when
both N-glycosylated asparagines were replaced by alanines or glutamines, but did not test
whether degradation occurred at the ER or in a later compartment. Our results clearly show
that unglycosylated CFTR is degraded after the protein has exited the ER.
Rapid turnover and decreased stability in the absence of N-linked glycosylation have also been
observed in other membrane proteins. Mutation of N-linked glycosylation sites of the human
κ opioid receptor led to a threefold faster turnover than that of the wild-type protein (Li et al.,
2007). Similarly, another ABC transporter, P-glycoprotein (ABCB1), turns over three times
faster when N-linked glycosylation is inhibited (Zhang et al., 2004). This degradation
apparently occurs as a consequence of increased ubiquitylation. Ubiquitylation of mature
CFTR has been shown to promote its targeting to lysosomal degradation (Sharma et al.,
2004) and, therefore, a similar mechanism might contribute to the faster turnover of non-
glycosylated CFTR.
As has been reported in previous studies, we did not find the chloride channel function of CFTR
to be affected by lack of N-glycosylation (Chang et al., 1994; Gregory et al., 1991; Morris et
al., 1993). Analogous to CFTR, the related ABC transporter P-glycoprotein functions without
attached oligosaccharides (Gribar et al., 2000; Kramer et al., 1995; Schinkel et al., 1993;
Urbatsch et al., 2001). Moreover, it has recently been shown that N-linked glycosylation is not
essential for expression, transport activity, or trafficking of another human ABC protein,
ABCG2 (Diop and Hrycyna, 2005; Mohrmann et al., 2005).
We found that the individual CFTR glycosylation mutants, with just one oligosaccharide chain
attached, behaved differently to each other in several respects. The CFTR variant with a single
oligosaccharide at position 894 (N900D) was much more susceptible to deglycosylation by
PNGase, whereas the variant with glycosylation at position 900 (N894D) was surprisingly
resistant to this treatment. PNGase is a cytoplasmic enzyme that catalyzes deglycosylation of
proteins during ERAD, before they are degraded by the proteasome, and it has been shown
that this N-glycanase acts specifically on denatured and misfolded proteins (Hirsch et al.,
2003; Hirsch et al., 2004; Joshi et al., 2005; Suzuki and Lennarz, 2003). This suggests that
N900D CFTR, with a glycan at position 894, might be a much better substrate for this pathway
than the N894D variant.
Pulse-chase labeling experiments demonstrated that the individual oligosaccharides do affect
the fate of the wild-type protein at the ER differently. With just the oligosaccharide chain at
position 900 (N894D), turnover was similar to that of the wild-type protein; however, with an
oligosaccharide attached only at position 894 (N900D), CFTR maturation was very inefficient.
When transport from the ER was inhibited by brefeldin A, the CFTR mutant with an
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oligosaccharide attached to position 894 was very unstable and was rapidly removed by ERAD
(Fig. 6B,C). The conclusion that N900D CFTR is a better substrate for ERAD than N894D
CFTR was further strengthened by the preferential interaction of N900D CFTR with EDEM,
which was similar to that of the wild-type protein, but which was reduced in the N894D mutant
(Fig. 7), and by the observation that the proteasomal inhibitor ALNN stabilized N900D CFTR,
but not N894D CFTR (supplementary material Fig. S4). It seems likely that the double mutant
behaves in the ER like CFTR N894D rather than like CFTR N900D, because the presence of
the oligosaccharide at N894 supports the ERAD pathway, whereas the absence of this
oligosaccharide allows the double glycosylation mutant to exit the ER and proceed to the Golgi
and plasma membrane.
The concept that each glycan of CFTR is capable of directing the processing of the protein at
the ER in a different way fits extraordinarily well with the results obtained in this study. We
suggest a model in which the oligosaccharide at position N894 accelerates ERAD, whereas the
oligosaccharide attached to position 900 promotes maturation and allows the protein to
progress to the Golgi (Fig. 8).
We cannot rule out the possibility that the lack of glycans might affect the conformation of
CFTR and that the N900D mutation is accompanied by a significant degree of misfolding that
makes it a better ERAD substrate. However, this does not seem a very likely scenario because
the double mutant, which lacks both oligosaccharide chains, is stable at the ER, similar to wild-
type CFTR.
Interestingly, distinct functions of N-glycans have been observed in the processing of other
glycoproteins. Hebert et al. (Hebert et al., 1997) reported that the number and location of
glycans on influenza hemagglutinin determined its folding and association with calnexin. In
another study, two out of eight N-glycosylation sites were shown to be the major determinants
for efficient apical sorting of the transmembrane protein endolyn (CD164) (Potter et al.,
2004). In case of the gastric H,K-ATPase β-subunit, just one out of four N-glycosylation sites
affected ER-to-Golgi trafficking and enhanced endocytosis from the apical membrane (Vagin
et al., 2004). In yeast, it has been observed that the N-linked oligosaccharides of CPY have
different impacts on the processing of the protein and the most C-terminal of the four N-linked
oligosaccharides is specifically required for ERAD (Kostova and Wolf, 2005; Spear and Ng,
2005).
The exact, molecular details of the means by which the individual glycans affect the processing
of CFTR are not yet apparent, but CFTR-interacting lectins, including calnexin and EDEM,
might act upon the variously glycosylated forms differentially (Fig. 8). The interactions of N-
linked carbohydrates of CFTR at the ER might not be limited to these two chaperones, but
could also involve lectin receptors such as ERGIC53 (LMAN1), VIP36 (LMAN2), VIPL
(LMAN2L) or erlectin, which have all been shown to facilitate trafficking of certain
glycoproteins in the early secretory pathway (Appenzeller-Herzog and Hauri,
2006;Appenzeller et al., 1999;Cruciat et al., 2006;Neve et al., 2003;Shimada et al., 2003).
In conclusion, the two N-linked oligosaccharides are not responsible for retention of ΔF508
CFTR at the ER, but they strongly influence turnover of the mature wild-type protein in post-
ER compartments. In addition, it is notable that each individual oligosaccharide chain directs
ER processing of CFTR differently. This might be due either to different oligosaccharide
structures at the two sites, or to differences in the accessibility of the N-glycans at their separate
locations in the polypeptide chain.
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Mutagenesis and stable expression of CFTR
Replacement of asparagine residues N894 and N900 with aspartate residues was achieved by
replacing a CFTR HpaI-DraIII cDNA fragment (bp 2463 to 3328) in pNUT CFTR with a
counterpart generated by PCR coding for N894D, N900D or N894D/N900D, to produce
CFTRs with only one or no glycosylation site (Chang et al., 1994). BHK-21 cells stably
expressing CFTR containing an external HA epitope in EL2 (Extope-CFTR) have been
described previously (Gentzsch et al., 2004). BHK-21 and CHO-K1 cells were transfected with
Lipofectamine (Invitrogen) or using calcium phosphate and propagated in media with 500 or
50 μM methotrexate, respectively.
Human excess donor lungs and excised recipient lungs were obtained at the time of lung
transplantation from portions of main stem or lumbar bronchi and cells were harvested by
enzymatic digestion as previously described (Fulcher et al., 2005) under a protocol approved
by the UNC Medical School institutional review board. To express Extope-CFTR in primary
human airway epithelial cultures, cells were seeded on collagen-coated Millicell culture plate
inserts and maintained at an air-liquid interface for 40-45 days. The well-differentiated cultures
were then transduced with adenoviral vectors as described previously (Coyne et al., 2000) to
express Extope-CFTR and Extope-ΔF508 with intact or mutated glycosylation sites (N894D/
N900D).
Immunofluorescence microscopy
Cells were fixed in 4% paraformaldehyde for 10 minutes and immunostaining was either
performed on non-permeabilized cells or on cells permeabilized with 0.1% saponin PBS. Cells
were blocked with 1% BSA and 5% normal goat serum in PBS. Primary antibodies were mouse
monoclonal anti-CFTR antibodies M3A7, 570 and 596 or anti-HA antibody HA11 (Covance).
Detection of the external HA epitope in EL2 of CFTR (Extope-CFTR) on non-permeabilized
BHK-21 cells was performed exactly as described previously (Gentzsch et al., 2004).
Secondary antibodies were goat anti-mouse IgGs conjugated to Alexa Fluor 488 or 568
(Molecular Probes).
For detection of cell-surface Extope-CFTR and variants, primary human airway epithelial
cultures were labeled with anti-HA antibody HA11 from the apical side for 30 minutes at room
temperature, then frozen culture sections were prepared, fixed, permeabilized, blocked and
treated with goat anti-mouse Alexa Fluor 488 conjugate.
Cell-surface ELISA
BHK-21 cells expressing externally tagged ΔF508 CFTR (Gentzsch et al., 2004) were seeded
in a 96-well plate at 40,000 cells per well. Cells were fixed, labeled with the HA11 antibody
that recognizes the external tag, followed by goat anti-mouse IgG conjugated to X-Sight 761
(Kodak). Plates were scanned with a LI-COR Odyssey infrared imaging system.
Immunoprecipitation and pulse-chase experiments
Immunoprecipitations were performed on NP40 cell lysates (1% Nonidet P40, 150 mM NaCl,
50 mM Tris-HCl pH 7.4, 10 mM NaMoO4) with protease inhibitors (1 μg/ml leupeptin, 2 μg/
ml aprotinin, 50 μg/ml pefabloc, 121 μg/ml benzamidine, 3.5 μg/ml E64) using mouse
monoclonal anti-CFTR antibody 596 crosslinked to Dynabeads Protein G (Invitrogen).
For metabolic labeling with [35S]methionine, cells were washed twice in methionine-free
αMEM (Gibco) and starved in the same medium for 30 minutes. [35S]methionine (100 μCi/
ml; Amersham) was then added and cells were labeled for 20 minutes. Cells were washed twice
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with regular growth medium supplemented with 1 mM methionine and chased for various
times. In some experiments, 10 μg/ml brefeldin A was added to the growth medium 12 hours
before labeling and was also present in all other incubations. Cells were lysed in RIPA buffer
(50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1% deoxycholic acid)
with protease inhibitors and CFTR was immunoprecipitated with monoclonal antibody M3A7
followed by incubation with protein G-Sepharose beads (Sigma). Immunoprecipitated proteins
were eluted with sample buffer and subjected to SDS-PAGE. The amount of labeled protein
remaining after the indicated chase periods was quantified by electronic autoradiography image
analysis using a Packard Instant Imager.
Deglycosylation and tunicamycin treatment
For N-glycosidase F digestion, 1% SDS cell lysates were diluted with 10 volumes of 100 mM
sodium phosphate buffer (pH 7.5) supplemented with 25 mM EDTA, 0.5% NP40, 1% β-
mercaptoethanol and protease inhibitors (1 μg/ml leupeptin, 2 μg/ml aprotinin, 50 μg/ml
pefabloc, 121 μg/ml benzamidine, 3.5 μg/ml E64). One unit of N-glycosidase F (Boehringer
Mannheim) was added and the samples incubated for various times at 37°C. To remove core-
glycosylated oligosaccharides, the lysates were diluted with 10 volumes of buffer (50 mM
sodium acetate pH 5.3, 0.5% NP40, protease inhibitors) to a final concentration of 0.1% SDS.
The samples were than incubated for 4 hours at 37°C with 0.01 U endoglycosidase H
(Boehringer Mannheim). Proteins were precipitated by addition of four volumes of cold
ethanol, dissolved in sample buffer, and subjected to SDS-PAGE.
To completely inhibit N-linked glycosylation of CFTR, BHK-21 cells that had been transiently
transfected with pcDNA3 CFTR were subsequently grown for 24 hours in medium containing
5 μg/ml tunicamycin.
Chloride efflux assay
Cells grown in 6-well culture dishes were washed twice with efflux buffer [136 mM NaNO3,
3 mM KNO3, 2 mM Ca(NO3)2, 2 mM Mg(NO3)2, 10 mM glucose, 20 mM HEPES pH 7.4]
and loaded with 36Cl by a 1 hour incubation with 0.5 ml efflux buffer containing 1 μCi
Na36Cl (Amersham). Chloride efflux was stimulated by addition of 1 mM IBMX, 10 μM
forskolin and 100 μM dibutyryl cAMP at time 0. Samples were collected at 1-minute intervals
into 24-well Top Count plates (Packard). MicroScint 40 (PerkinElmer) was added for
scintillation counting.
Single-channel measurements
Microsomal membrane vesicles were isolated from BHK-21 cells stably expressing the
different CFTR variants, phosphorylated with protein kinase A and single-channel kinetics
were recorded as described previously (Aleksandrov and Riordan, 1998) (supplementary
material Fig. S1).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Comparison of the sequences coding for the two potential N-glycosylation sites, 894 and 900,
in extracellular loop 4 of CFTR. Sequences of mammalian CFTRs were aligned using FASTA.
Amino acids fitting the consensus N-X-S/T for asparagine-linked glycosylation are
highlighted. X can be any amino acid residue other than proline (Imperiali and Hendrickson,
1995).
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Unglycosylated CFTR does not bind to calnexin but functions as a chloride channel. (A)
Western blot of CFTR and unglycosylated CFTR created either by mutation of the
glycosylation sites (N894D/N900D) or by expressing CFTR in tunicamycin-treated cells (+
Tunicamycin). CFTR and CFTR N894D/N900D variants were stably (left panel) or transiently
(right panel) expressed in BHK-21 cells. Tunicamycin (5 μg/ml) was added directly after
transient transfection to achieve complete inhibition of N-linked glycosylation. CFTR was
detected in the microsomal membrane vesicle fraction by western blotting using mouse
monoclonal anti-CFTR antibody 596. (B) CFTR N894D/N900D does not interact with
calnexin. CFTR was immunoprecipitated by incubation with anti-CFTR antibody 596
crosslinked to Dynabeads (as indicated on the left). CFTR and calnexin (CNX) were detected
by western blotting using mouse monoclonal antibody 596 for CFTR or rabbit polyclonal
antibody SPA860 (Stressgen) for calnexin (as indicated on the right). Molecular weight marker
positions (kDa) are indicated on the left. (C) The channel properties of unglycosylated CFTR
are similar to wild-type CFTR. Single-channel measurements were performed using membrane
vesicles prepared from stably transfected BHK-CFTR, BHK-N894D/N900D cells or from cells
transiently transfected with CFTR that were treated with tunicamycin. Tunicamycin (5 μg/ml)
was added directly after transient transfection to achieve complete inhibition of N-linked
glycosylation.
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ΔF508 N894D/N900D cannot escape ER quality control. (A) Western blot of CFTR, CFTR
N894D/N900D, ΔF508 and ΔF508 N894D/N900D expressed in BHK-21 cells. Lysates were
separated by SDS-PAGE and CFTR was detected after transfer to nitrocellulose by mouse
monoclonal anti-CFTR antibody 570. (B) ΔF508 N894D/N900D does not interact with
calnexin. ΔF508 N894D/N900D was immunoprecipitated by incubation with anti-CFTR
antibody 596 crosslinked to Dynabeads. CFTR and calnexin (CNX) were detected by western
blotting using mouse monoclonal antibody 596 for CFTR or rabbit polyclonal antibody
SPA860 for calnexin. Molecular weight marker positions (kDa) are indicated on the left. (C)
Immunofluorescence microscopy of CFTR and ΔF508 glycosylation variants in permeabilized
cells. Immunostaining was performed on permeabilized BHK-21 cells using anti-CFTR mouse
monoclonal antibody 570, followed by goat anti-mouse IgG Alexa Fluor 488 conjugate.
Calnexin was stained to visualize the ER compartment using rabbit anti-calnexin antibodies
followed by goat anti-rabbit IgG Alexa Fluor 568 conjugate. (D) Visualization of cell-surface
CFTR on non-permeabilized cells by applying antibody HA11 to detect the external HA
epitope in EL2 of CFTR variants. Cells were grown at 37°C or incubated at 27°C for 48 hours
in the presence of 2 mM sodium butyrate to promote cell-surface expression of Extope-ΔF508
CFTR. (E) cAMP-stimulated 36Cl- efflux measurements of stably expressing BHK-CFTR
cells. Stimulation cocktail was added (+) at time 0. Each point represents the average of three
independent samples and standard deviations are indicated. (F) Immunostaining of CFTR and
ΔF508 glycosylation variants in virally transduced well-differentiated primary human airway
epithelial cells. All pools of intracellular CFTRs were stained on frozen sections of cultures
grown at 37°C with HA11 antibody followed by goat anti-mouse IgG Alexa 488 conjugate.
(G) Labeling of apical CFTR in virally transduced well-differentiated primary human airway
epithelial cells. Cultures were incubated at 27°C for 48 hours and the apical pool of CFTR
variants was labeled with HA11 antibody; cultures were then frozen in OCT and frozen sections
labeled with goat anti-mouse Alexa 488 conjugate. Scale bars: 10 μm.
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EDEM binds CFTR and accelerates its degradation, but neither the inhibition of EDEM
interaction nor of calnexin interaction can rescue ΔF508 CFTR. (A) CFTR was
immunoprecipitated from cells transiently expressing HA-tagged EDEM by anti-CFTR
monoclonal antibody 596 crosslinked to Dynabeads. EDEM was detected by western blotting
using monoclonal antibody HA11 and CFTR was detected by antibody 596. (B) CFTR was
expressed transiently in BHK-21 cells alone or together with EDEM using pcDNA3 CFTR
and pCMV-SPORT2 EDEM, respectively. In the case of CFTR expression alone, similar
amounts of empty control vector were co-transfected with the CFTR plasmid. (C)
Immunofluorescence microscopy of ΔF508 CFTR expressed in BHK-21 cells that were treated
with various glycosidase inhibitors or tunicamycin. CAS (castanospermine, 0.2 mM) inhibits
glucosidase I; DMM (1-deoxymannojirimycin, 0.5 mM) and kifunensine (0.2 mM) are
inhibitors of mannosidase I; and tunicamycin (10 μg/ml) completely blocks N-glycosylation.
The activity of these compounds was confirmed (supplementary material Fig. S3; Fig. 2A).
Inhibitors were added to the growth media for 18 hours at the concentrations indicated and
ΔF508 CFTR was visualized on permeabilized cells using anti-CFTR monoclonal antibody
596 followed by goat anti mouse IgG Alexa Fluor 488 conjugate. Scale bar: 10 μm. (D) Cell-
surface ELISA showing that glycosidase inhibitors do not rescue ΔF508. BHK-21 cells
expressing an externally tagged ΔF508 CFTR (Gentzsch et al., 2004) were seeded in a 96-well
plate at 40,000 cells per well. Twenty-four hours after seeding, cells were treated for 20 hours
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with CAS (0.4 mM), DMM (0.5 mM), KIF (kifunensine, 0.2 mM) or tunicamycin (10 μg/ml).
Corrector compounds C3 (VRT-325) and C4 (corr-4a), which have been reported to partially
rescue ΔF508 CFTR (Loo et al., 2005; Pedemonte et al., 2005; Van Goor et al., 2006), were
used as positive control at 20 μM each. Cells were fixed, labeled with HA11 antibody that
recognizes the external tag, followed by goat anti-mouse IgG conjugated to X-Sight 761 and
scanned with an infrared imaging system. A significant increase in the cell-surface pool of
ΔF508 CFTR was observed on treatment with C3 and C4 (*P<0.0001). Neither treatment with
glycosidase inhibitors nor complete inhibition of N-glycosylation by tunicamycin had an effect
that was significantly different from the no-drug control. Data represent the average of eight
wells; bars indicate s.e.m. Statistical significance was determined using an unpaired Student’s
t-test. The blue line indicates the baseline level of the no-drug control.
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Mutagenesis and enzymatic deglycosylation of individual CFTR N-glycosylation sites. (A)
Western blot of CFTR variants N-glycosylated at both, either, or neither of the two native sites.
1% SDS lysates of stably expressing CHO cells were resolved on 6% polyacrylamide gels,
transferred to nitrocellulose and probed with mouse monoclonal antibody M3A7. (B)
Endoglycosidase H treatment of CFTR individual glycosylation site mutants. Total cell lysates
were incubated with (+) or without (-) endoglycosidase H at 37°C for 4 hours and analyzed by
western blotting. The arrowheads indicate core-glycosylated protein or protein deglycosylated
by endoglycosidase H. (C) Individual glycosylation site variants have different sensitivities
towards deglycosylation by N-glycanase. Lysates of stably expressing CHO cells were
incubated with 1 U N-glycosidase F at 37°C for 0 (lane 1), 10 minutes (lane 2), 20 minutes
(lane 3) or 24 hours (lane 4) and subjected to SDS-PAGE and western blotting.
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Turnover of CFTR glycosylation site variants with a single N-linked oligosaccharide. (A)
Glycosylation site variant maturation and turnover as monitored by metabolic pulse-chase
labeling. Cells were washed twice with methionine-free αMEM and starved for 30 minutes in
the same medium. [35S]methionine was added to allow incorporation during a 20-minute pulse.
Cells were then maintained in medium supplemented with 1 mM methionine, lysed with RIPA
buffer at the times indicated, CFTR protein immunoprecipitated and the eluted proteins
resolved on 7% polyacrylamide gels. (B) Effect of brefeldin A on turnover of glycosylation
site variants. Wild-type and variant CFTR proteins were labeled in the presence of brefeldin
A and pulse-chase experiments performed as described in A and Materials and Methods. (C)
The amount of labeled protein remaining after the indicated chase periods was quantified by
electronic autoradiography image analysis and is shown as a percentage of the initial label.
Chang et al. Page 21














Interaction of N894D and N900D single-chain mutants with calnexin and EDEM. (A) Cell
lysates from BHK-21 cells stably expressing CFTR, CFTR N894D, CFTR N900D or CFTR
N894D/N900D were subjected to immunoprecipitation by incubation with anti-CFTR
antibody 596 crosslinked to Dynabeads (IP: CFTR, as indicated on the left). CFTR and calnexin
(CNX) were detected by western blotting using mouse monoclonal antibody 596 for CFTR or
rabbit polyclonal antibody SPA860 for calnexin (as indicated on the right). Molecular weight
marker positions (kDa) are indicated on the left. (B) CFTR was immunoprecipitated from cells
that were stably expressing CFTR, CFTR N894D, CFTR N900D or CFTR N894D/N900D and
that were also transiently expressing HA-tagged EDEM, by incubation with anti-CFTR
monoclonal antibody 596 crosslinked to Dynabeads. EDEM was detected by western blotting
using monoclonal antibody HA11 and CFTR using antibody 596.
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Individual N-linked oligosaccharides promote different fates in the processing of CFTR.
Immediately after addition of the core glycan to the nascent polypeptide chain, the outermost
of the three glucose residues is removed by glucosidase I. Subsequently, glucosidase II removes
the next glucose residue. The resulting monoglucosylated core glycans bind to calnexin. When
glucosidase II removes the remaining glucose residue, the glycoprotein dissociates from
calnexin and, if properly folded, is free to leave the ER. If the protein is incompletely folded
it is reglucosylated by the UDP-glucose:glycoprotein glucosyltransferase, creating again a
monoglycosylated core oligosaccharide that can bind to calnexin. Proteins that have stayed in
the ER for too long and are terminally misfolded become a substrate for α-mannosidase I. The
trimmed oligosaccharide binds to EDEM (ER degradation-enhancing α-mannosidase-like
protein) and the glycoprotein is consequently directed towards ERAD (ER-associated
degradation). The carbohydrate at position 900 in CFTR N894D supports the route to
maturation and progress to the Golgi, whereas the oligosaccharide at asparagine residue 894
in N900D promotes degradation.
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